Syncom Formulations (India) Ltd. — Interim / Quarterly Report 2025

Feb 12, 2026

SYNCOM/SE/2025-26 12th February, 2026

Online filing at: www.listing.bseindia.com and https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp

To,

To, BSE Limited Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai (M.H.) 400 001 BSE CODE:524470

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai- 400051 NSE SYMBOL: SYNCOMF

Subject: Regulation 33(3) of SEBI (LODR) Regulations, 2015 - Submission of Standalone & Consolidated Unaudited Financial Results along with Limited Review Report, for the quarter and Nine months ended on 31st December, 2025.

Dear Sir/Ma'am

This is in continuation of our letter no. SYNCOM/SE/2025-26 dated 04th February, 2026 regarding intimation of Board meeting for consideration and approval of Standalone and Consolidated Un-Audited Financial Results for the Quarter and Nine months ended 31st December, 2025.

Pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015, we are pleased to submit the following:

• 1. Standalone and Consolidated Un-Audited Financial Results of the Company for the Quarter and Nine months ended 31st December, 2025;
• 1. Standalone and Consolidated Limited Review Report by the Statutory Auditors of the company for the Quarter and Nine months ended 31st December, 2025;

which was considered and approved by the Board at their Meeting held on Thursday, the 12th February, 2026 at 3:00 P.M. and Concluded at 4:30 P.M.

We are also in process to file the aforesaid financial results in XBRL format within the stipulated time and the same shall also be hosted on the website of the company.

The Financial Results will also be published in widely circulated English and Marathi (Vernacular) newspaper in the prescribed format within the stipulated time period.

The Board Meeting commenced at 3:00 P.M. and Concluded at 4:30 P.M. You are requested to take on record the unaudited Financial Results along with Limited Review Report for your reference and record.

Thanking You, Yours Faithfully, For, SYNCOM FORMULATIONS (INDIA) LIMITED CS VAISHALI AGRAWAL COMPANY SECRETARY & COMPLIANCE OFFICER Encl: a/a Vaishali Agrawal Digitally signed by Vaishali Agrawal Date: 2026.02.12 16:33:49 +05'30'

SANJAY MEHTA & ASSOGIATES

Ch artered Accountants

Limited Review Report on Un-audited Standalone Financial Results for the Quarter ended 31't December, 2025 pursuant to Regulation 33 of the SEBI (LODR) Regulations,2015

To, The Board of Directors SYNCOM FORMULATTONS (rNDrA) LTMTTED ln\$ore (M.P.)

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of SYNCOM FORMULATIONS (INDIA) LIMITED ("the Company"), for the period ended Decenrber, 31,2025 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations,2015, as amended including relevant circular issued by the SEBI from tirne to time.

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting" ("fND AS 34"), prescribed under Section I33 of the Companies Act, 2073, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations,2Ol5, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of oompany personnel and analytical procedures applied to financial data anC thus provirJe less assurance than an audit. We have not perfonned an audit and accordingly, rve do not express an audit opinion.

Based on our revierv conducted as stated above, rrothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations.20lS,including the manner irr which it is to be disclosed, or that it contains any material misstatement.

Place: lndore Date z 12-02-2026 CA Manish Mi

(Partner) M. No.079452 Chartered Accountants F-RN: 011524C o I

For, Sanjay Mehta &Associates

UDIN : 2607 9 452EGPPEM5738

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd. Off :- 7,Niraj Industrial Estate, Of Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

^EMail:- finance@sfil.in, Website:- www.siil.in, CIN :- L24239MH1988PLC047759

	STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS END					ED 31ST DECEMBER » 2025
7 0,	Particulars		Quarter Ended			(Rs.In Lakhs) ( Except EF'S) Year to date Ended	Year Ended
		Unaudited	34/42/2025 30/09/2025 34/12/2024			31/42/2025 31/12/2024 31/03/2025
1	[Revenue from Operations		Unaudited Unaudited		Unaudited	Unaudited	Audited
2	Other Income	11459.05 548.39	12143.51 523.44	42702.92 382.49	35257.25 1673.80	31438,60 1028.81	46284.93
3_	[Total Income (1 +2)	12007.44	12666.95	13085.44	36931.05	32467.41	1719.12 48004.05
4	EXPENSES (4) Cosl of materials consumed (b ) Purchases of Stock-in-Trade (c ) Changes in inventories of finished goads, Slock-in- Trade and work-in-progress	4744.91 1557.44	4642.63 1535.33	7626.18 712,91	15348.84 4654.70	19786.86 2379.23	27802.93 3947.71
	(4) Employee benefits expense	(217.97)	909.36	323.08	75.00	(1501.04)	(1062.24)
	(€) Finance costs	1745.26	1873.08	1394.75	5013.78	3719.90	5217.37
	(t) Depreciation and amortization expense	25.00	25.03	21,23	73.77	76.10	86.02
	(9) Other expenses	136.00	135.00	130.75	405.00	390.75	519,39
	Total expenses ( 4)	1511.98	1510.77	1186.03	4597.69	3450.30	5028.63
5	Profitiloss)	9502.62	10431,20	11394,93	30168,78	28302.12	41538.81
8	before exceptional items and tax (3-4) Exceptional Items	2504.82	2235.75	1690.48	6762.27	4165.29	6465.24
	7 _ Profiti(loss) before tax (5-6)	0.00	0.00	0.00	4.13	(0.24)	0.58
8	Tax expense:	2504.82	2235.75	1690.48	6766.40	4165.05	6466.82
	(1) Current tax (2) Deferred tax	600.12 18.36	522.00	402.82	1563.72	995.14	1445.26
3	Profit (Loss) for the period from Continuing operations (7-		29.64	8.54	69.30	32.93	133.98
10	iB)	1886.34	1684.14	1279.12	5143.38	3136.98	4887.16
11	Profit/(loss) from discontinued operations 'Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12	Profit/(loss) from Disconlinued operations (after tax) (10-11)	0.00 0.00	0.00 0.00	0.00 0.00	0.00	0.00	0,00
13	Profit(ioss) for the period { 9 + 12 }	1886.34	1684.11	1279.12	0.00 5143.38	0.00 3136.98	0.0C
14	Other Comprehensive Income A(/llems that will not be reclassified to prefil or loss (#) Income tax relating to ilems that will not be reclassified lo	0.00	0.00	0.00	0.00	0.00	4887.18 0.00
	profit or loss	0.00	0.00	0.00	0,00
	B (7) Items that will be reclassified to profit or loss	236.18	(5,58)	18.40	634.44	0.00 686.21	0.00 458.02
	(#) Income tax relating to items that will be reclassified to profit or loss
15	Total Comprehensive Income for the period (XIIl+XIV) (Comprising Profit (Loss) and Other Comprehensive) income for the period)	0.00 2122.52	0.00 1678.53	0.00 1297.52	0.00 5777.82	0.00	0,00
16	Paid up Share Capital of the Company (Face Value 1+)	9400.00	9400.00	9400.00	9400.00	3823.19 9400.00	5345.20
17	Reserves excluding revalualion reserves	=			5	=	9400.00
18	Eamings per equily share (for continuing operation):						24590.38
19	(1) Basic (2) Diluted Eamings per equity share (for discontinued operation):	0.23 0.23	0.18 0.18	0.14 0.14	0.61 0.61	0.41 0.41	0.57 0.57
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0,00
20	(2) Diluted Earnings per equity share {for discontinued & continuing operations)	0.00	0.00	0.00	0.00	0,00	0.00
	(1) Basic (2) Diluted	0.23 0.23	0.18 0.18	0.14 0.14	0.61 0.61	0.41 0.41	0.57 0.57

Date: 12/02/2026

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd. Off :- 7,Niraj Industria! Estate. Off Mahakali Caves Road, Andheri (E) Mumbai 400093

Works:- 256-257, Sector - 1, Pitharpur, Dist: Dhar-454775

E Mail finance@sfil.in, Website: www,sfil.in, CIN :- L24239MH1886PLC047759

S. No.	Particulars		Quarter Ended			Year to date Ended
		31/12/2025	30/09/2025	31/12/2024	31/12/2025	31/12/2024	31/03/2025
			Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue
	a) Pharmaceuticals Drugs & Formulations	11917.80	12567.69	12766.27	36548.01	31570.03	46,784.92
	b) Trading of Commodities	1.44	0.00	228.88	106.00	612.39	825.84
	c) Renting of Property Total Segment Ravenue	88.20	99.26	90,26	277.04	284.99	393.29
	Less: Inter Segment Revenue	12007.44	12666.95	13085.41	36931.05	32467.41	48,004.05
	Revenue from Operations	0,00	0.00	0.00	0.00	0.00	0.00
$\overline{a}$	Segment Results Profit(+)/Loss(-) before tax	12007.44	12665.95	13085,41	36931.05	32467.41	48,004.05
	and interest from each segment
	a) Pharmaceuticals Drugs & Formulations	2447.26	2167.52	1626.16	6579.43	3964,21	6,169,90
	b) Trading of Commodities	0.37	0.00	3.37	1.72	16,16	20.35
	c) Renting of Property	82.19	93.26	82.18	259.02	260.78	360.59
	Total Profit before tax	2529.82	2260.78	1711.71	6840.17	4241.15	6,550.84
	Less: i) Interest	25.00	25.03	21.23	73.77	76.10	85.02
	ii) Other Un-allocable Expenditure	0.00	0.00	0.00	0.00	0.00	0.00
	Profit before tax	2504.82	2235.75	1690.48	6766.40	4165,05	6,465.82
$\overline{a}$	(Segment Asset-Segment Liabilities)
	Sugment Asset
	a) Pharmaceuticals Drugs & Formulations	45198.48	40128.78	32536.81	45198.48	32536.81	35,752.01
	b) Trading of Commodities	179.35	251.35	890.60	179.35	890.60	448,67
	c) Renting of Property	3853.87	4733.44	4733.45	3853.87	4733.45	4,767.98
	Total Segment Asset	49231.70	45113,57	38160,86	49231.70	38160.86	40,968.66
	Un-allocable Assets	0.00	0.00	0.00	0.00	0.00	0.00
	Net Segment Asset	49231.70	45113.57	38160.86	49231.70	38160,86	40,968.66
	Segment Liabilities
	a) Pharmaceuticals Drugs & Formulations	9371.45	7332.38	5460.01	9371.45	5460.01	6,754.47
	(b) Trading of Commodities	0.00	2:11	155.00	0.00	155.00	82,76
	c) Renting of Property	92.05	133.40	77.48	92.05	77.48	141.04
	Total Segment Liabilities	9463.50	7467.89	5692.49	9463.50	5692.49	6,978.27
	Un-allocable Liabilities	0.00	0.00	0.00	0.00	0.00	0.00
	Net Segment Liabilities	9463.50	7467.89	5692.49	3463.50	5692.49	6,978.27

Notes:-

1 The above results were reviewed by the Audit Committee and approved by the Board at ils meeting held on 12/02/2026.

2 These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section | 33 of the Companies Acl, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.

3 The company is operating in 3 segments i.e. (a} Pharmaceuticals Drugs & Formulalions (b) Trading of Commodities (c) Renting of Property, particulars of segment wise resulls are given as required,

4 As required under Regulation 33 of SEB] (LODR) Regulations, 2015 the limited review by the Statutary Auditors have been completed for the quarter and Mine months ended on 31st December 2025, The report does not have any impact on the above results and notes which needs explanation.

5 Previous period figures have been regrouped/reciassified wherever necessary to confirm {o this period classification.

6 The Government of India has nolified four Labour Codes - namely the Code on Wages, 209, the Industrial Relations Cade, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Condilions Code, 2020 - with effect from 21 November 2025, which consolidates 29 existing labour laws. The Ministry of Labour & Employment has published draft Central Rules and FAQs on these codes, but the relevant rules are yel to be notified. Based on the available information as at reporting date, no material liabilily is envisaged in this regard. Financial impact will be reviewed once the relevant rules are notified

7 The Company has received an intimation regarding rejection of appeal and demand of 270,89,302 towards ineligible Input Tax Credit along with equivalent penalty under Sections 74(5) and 122 of the CGST Act, 2017 (total \$4,41,78,604). The Company is oblaining legal advice and proposes to contest the matter by filing an appeal before {he appropriate appellate authority

Place: Indore

SANJAY MEHTA & ASSOGIATES

Ch artered Accountants

Limited Review Report on Un-audited Consolidated Financial Results for the euarter ended 31'tDecember,2D2l pursuant to Regulation 33 of the SEBI (LODR) Regulations,2015

To, The Board of Directors SYNCOM FORMULATIONS (INDIA) LIMITED Indore (M.P.)

• 1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of SYNCOM FORMULATIONS (INDIA) LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the period ende{ December 31,2025 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015. as amended including relevant circular issued by the SEBI frorn time to time.
• 1. This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognitiol and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting" ("[ND AS 34"), prescribed under Section 133 of the Companies Act,2}l3,and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review
• 1. We conductecl our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review ctf Interim Financial Information performed by the Independent.Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

S. No.	Name of the Company	Relationship with the
		Holding Company
L	Sante Biotech Pvt. Ltd.	Wholly Owned Subsidiary
?,	Synmex Pharma Pvt. Ltd.	Wholly Owned Subsidiary _
J.	VillIIiotech International Pvt. Ltd.	Wholly Owned Subsidiary

1. The Statement includes the results of the following entity:

1. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2Ol5,including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore Date z 12-02-2026

For, Sanjay Mehta &Associates Chartered Accmrntants FRN: 011524

(Partner) M. No.079452 UDIN z 2607 9 452SWVJTE2257

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd. Off - 7, Niraj Industrial E state, Of Mahakati Caves Road,Andheri (E) Mumbal-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

^EMail: financegstilin, Website:- www. sfiLin, CIN \ L24239MH1geBPLCod77E59 CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31ST DECEMBER , ²⁰²⁵

Ss.	Particulars				Rs. In Lacs except EPS)
No,		Quarter Ended			Year to date ended		Year Ended
		31/12/2025 Unaudited	30/09/2025 Unaudited	31/12/2024 Unaudited	31/12/2026	31/12/2024	31/03/2025
1	Revenue from Operations	11544.06	42171,74		Unaudited	Unaudited	"Audited
2	Other Income	559.09	\$25.05	12753.32	35375.97	31613.62	4650126
a)	_[fetatincame (1 #2)	12064.15	12696,79	403.70	1678.61	1049.12	1743.40
4	EXPENSES			13167.02	37054.58	32662,74	48244.56
	(a) Cost of materials consumed	4744.91	4642.63	7626.18
	(b ) Purchases of Stock-in-Trade {¢ ) Changes in inventories of finished goods, Stock-in- Trade	1571.08	1829.19	722.62	1534884 4666.34	1978688 2417.47	27802.93
	and work-in-progress	(212,32)					3995,75
	(4) Employee benefits expense	1745.26	\$03.74 1673.08	316.76	78.91	(1507.36)	(1066.15);
	(€) Finance costs	26.34		1394.75	5013.78	3719.90	5217.87
	(f) Depreciation and amortization expense	136.00	26.49 135.00	19.82	77.91	74.84	86.49
	(9 ) Other expenses			130.75	405.00	300.75	519.39
	Total expenses {4 )	1544.08	1583.10	1219,92	4724.24	3558.79	5137.19
6	Profit(ioss) before exceptional items and tax (3+ 4)	9555.35	10493,44	14430.80	30317,02	20441.24	44693,97
6	[Exceptional Items	2508.80	2203.65	1726.22	6737.56	4221.50	6550.69
	7 _ Profiti(iogs) before tax (5-6)	0.00	0.00	0.00	4.13	(0,24)	0.53
§	iTax expense:	2608.80	2203.65	1726.22	6761.69	4221.26	6551.27
	(1) Current tax	599.63	513.90
	(2) Deferred tax	18.38	29.64	417.61 8.41	1546.03 69.30	1014.43	1474.43
g)	Profit (Loss) for the period from continuing operations (74 8)					32.80	133,38
10	Profiti(loss) from discontinued operations	1690,61	1660.14	1300.20	\$126.36	3474.03	4943.46
14	'Tax expense of discontinued operations	0.00	0.00	0,00	0.00	0.00	0.0u
12	Profit/(loss) from Discontinued Operations (after tax) (10-11)	0.00	0.00	0,00	0.00	0.00	0.00
		0.00	0.00.	0,00	o.oo
13	Profiv(loss) for the period § + 12)	1890.81	1660.11	1300.20	5126.36	0.00 3174.03	o.oo
14	Other Comprenensive Income						4943.46
	A(/}ltems that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(#) Income tax relaling to items that will not be reclassified taj profit or loss
	3 (7) tems that will be reclassified lo profit or loss	0.00	0.00.	0.00	0.00	000	0.00
	(#) Income tax relating lo items that will be reclassified to profit	236.18	(5.58)	18.40	634,44	686,21	458,02
	ar loss	0,00	6.00	0.00
15	Total Comprehensive income for the Period [Xtl+xIV)				0.00	a.00	0.00
	(Comprising Profit {Loss} and Other Comprehensive, Income for the period)
16	Paid up Share Capital of the Company (Face Value 1/-)	2126.99	1664.63	1318.60	5760.80	3860.24	5401.48
1?	[Reserves excluding revaluation reserves	9400.00	9400,00	9400.00	9400.00	9400.00	9400.00
18	Earnings per equity share (for continuing operation)	z	Fe	=		-	2481576
	(1) Basic
	(2) Diluted	0.23 0.23	0.18	0.14	0.61	0.41	057
19	Earnings per equity share (for discontinued operation):		0.18	0.14	0.61	0.41	O57
	(1) Basic	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
20	Eamings per equity share (for discontnued & Continuing			0.00	0.00	0.00	0.00
	Operations)
	(1) Basic (2) Diluted	0.23	018	0.14	0.61	0.41	0.57
		0.23	0.18	0.14	0.61	0.41	0.57

Place: Indore

Date: 12/02/2026

SYNCOM FORMULATIONS (INDIA) LIMITER

Regd.Off :- 7,Niraj Industral Estate, Off Mahakali Caves Road, Andheri (E) Mumbai 400093

Works.- 256-257, Sector - 1, Pilhampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1888PLC047759

	Picts		Quarter Ended			Year to date ended	Year Ended
SN;		34/12/2028 Unaudited	yorosizozs Unaudited	sinziaoas Unaudited	34/2202 Unaudited	31M202 Unaudited	4103/2025 Audited
4	[Segment Revenue
	a) Pharmaceuticals Drugs & Formulations	41,974.95)	12,587.88	12839.41	36672.89)	767,79	47,027/33
	lb) Trading of Commodities	1.44]	0.00)	226.88)	106:00)	612.3	825.84
	ic) Renling of Property	87,75	95.81	68.73]	275.69)	282,	35148
	Total Segment Revenue	12,084,15)	12,696.75	13157.02]	37,054.58)	32,662.74]	48,244.66)
	Lees: Inter Segmant Revenue	a	0.00)	0.00)	6.00]	0.00)	0.00)
	Revenue from Operations	412,064,4	12,696,79)	43457.0.	37,054, 58)	32,662.74]	48,244.66)
2.	[Segment Results Profit(+/Loss -) before tax and Interest from ¢ach segment
	a} Pharmaceuticals Drugs & Formulations	2,456.03	2,431,23)	1662.02	6560.24	4021.5:	6,258,862)
	bi Trading of Commodities	0.37]	O00)	3.37)	1.72	16,1	20.35)
	tc) Renting of Property	75,74	'3a81	60.65)	257.67	258.3!	358.78)
	Total Profit before tax	2,595, 14)	2,230.14)	1746.04!	6,819.60)	4,296.07]	a 6,637.76)
	Lene: ) Interest	2604	76.40]	78.82	7784	a)
	H) Other Un-allocable Expenditure	0,00)	6.00)	6.00	9,09)	0.00)	0.00
	Profit before tax.	2,508.80)	2,203.68]	1726.22	6,741.69)	4,224.26]	6,661.27
3.	[[Seqment Asset-Segment Liabilities)
	Segment Asset
	a) Pharmaceuticals Drugs & Formulations	45,481.37]	40,623.55)	2946.55)	45481.37]	32846,65)	36,111,42
	i») Trading of Commodities	178,60)	251,35)	850.60)	178.80)	890,60)	448.67
	6) Renting of Property	3,853.87]	4,730,448	4733.45)	3653.87]	4733.45	4,767.98
	Total Segment Asset	49,614.04)	45,608.34)	78570.60)	49,674.04)	38,570.69]	44,328.07]
	Un-allocable Assets			0.00)		0.00}	-
	Net Segment Asset	49,544.04	45,608.24)	38670.60)	49,514,04)	34,870.60)	441,328.07]
	Segment Liabilities
	a} Pharmaceuticals Drugs & Formulations	8,446.14)	7 623.26)	\$663.84)	gap. 14	5663.64]	6,888.49
	ib} Trading of Commodities	0.00)	2	165.00)	0.00)	155,00} Tag	82.76
	c} Renting of Property	91.97}	\$33.40}	77,43	81.97]		141.04 T4229)
	Total Segment Liabilities	9,840.11	7,758.77)	\$896.0	9,640.14	5,896.07]
	Un-allocable Liabilities	0.00)	0,00)	= 6.00	0.01	0.00)	a.00) TAZ29
	Net Segment Liabilities	Lala	7,758.77		9,540.14]	5,856.07

Notes:-

Place: Date: 12/02/2026

1 The above resulis were reviewed by the Audit Committee and approved by the Board at its meeting held on 12/02/2026

²These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, ²⁰¹³ read with Companies (Indian Accounting Standards) Rules 2015 as amended fram time to time.

²The company is operating in 3 segments i.e. (8) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required

⁴As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter anded on 31st December, 2025. The report does not have any impact on the above results and notes which needs explanation,

⁵Previous period figures have been regroupedireciassified wherever necessary to confirm to this period classification.

⁶The Company currently have 3 (three) Wholly Owned Subsidiaries namely Synmex Pharma Pvt. Ltd., Sante Biotech Pvt Ltd. And Vincit Biotech Intemational Pvt. Ltd.

⁷The Government of /adis has nolified four Labour Codes - namely the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code. 2020 - with effect fram 21 November 2025, which consolidates 29 existing labour laws. The Ministry of Labour & Employment has published draft Central Rules and FAQs on these codes, but the relevant rules are yet lo be notified. Based on the available information as al reporting date, no material Bablity is envisaged 9 tes regard, Financial impact will be reviewed once the relevant rules are notified.

⁸Syncom has received an intimation regarding rejection of appeal and demand of 270,89,302 towards ineligible Inpul Tax Credit along with equivalent penalty under Sections 74(5) and 122 of the CGST Act, 2017 (total €1,41,76,604), The Company is obtaining legal advice and proposes to contest the matter by filing an appeal before the appropriate appellate authority.

Ankit Kedarmal Bankda an & Wholetime Director Din : 02359461